| Literature DB >> 32023913 |
Nittiya Suwannasom1,2, Ijad Kao1, Axel Pruß1, Radostina Georgieva1,3, Hans Bäumler1.
Abstract
Riboflavin (RF) is a water-soluble member of the B-vitamin family. Sufficient dietary and supplemental RF intake appears to have a protective effect on various medical conditions such as sepsis, ischemia etc., while it also contributes to the reduction in the risk of some forms of cancer in humans. These biological effects of RF have been widely studied for their anti-oxidant, anti-aging, anti-inflammatory, anti-nociceptive and anti-cancer properties. Moreover, the combination of RF and other compounds or drugs can have a wide variety of effects and protective properties, and diminish the toxic effect of drugs in several treatments. Research has been done in order to review the latest findings about the link between RF and different clinical aberrations. Since further studies have been published in this field, it is appropriate to consider a re-evaluation of the importance of RF in terms of its beneficial properties.Entities:
Keywords: cancer; complementary medicine; functional food; muscular degeneration; neurodegeneration; oxidative stress; riboflavin; vitamin B2
Mesh:
Substances:
Year: 2020 PMID: 32023913 PMCID: PMC7037471 DOI: 10.3390/ijms21030950
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Flavin content of selected human body fluids (mol L−1) and organs (mol per kg of dry matter) [1].
| Riboflavin | FAD | FMN | |
|---|---|---|---|
| Skin | 7.6 × 10−6 | — | — |
| Cerebral cortex | 7.2 × 10−6 | — | — |
| Myocardium | 3.2 × 10−5 | — | — |
| Pectoral muscle | 7.2 × 10−6 | — | — |
| Aortic tissue | 4.8 × 10−7 | 9.7 × 10−7 | 2.2 × 10−7 |
| Erythrocyte | 1.4 × 10−7 | 4.3 × 10−7 | 2.8 × 10−8 |
| Plasma | 1.0 × 10−8 | 6.3 × 10−8 | 7.5 × 10−9 |
| Eye-fluid | 4.5 × 10−6 | — | — |
Figure 1Structure of (a) Riboflavin (RF), (b) Flavin monophosphate (FMN), and (c) Flavin adenine dinucleotide (FAD). ChemDraw (PerkinElmer Informatics, Inc. MA, USA).
Figure 2RF is an essential vitamin for multiple physiological aspects in the body.
Evidence on effect of RF and its roles for reactive oxygen species in various symptoms and diseases. Upregulation ↑, downregulation ↓.
| Model | Dose | Antioxidant Enzymes | Key Findings | References |
|---|---|---|---|---|
| Anti-aging in Drosophila melanogaster (fruit fly) | RF at 120 µg/mL | SOD1 ↑; CAT ↑; lipofuscin (LF) ↓ | RF prolonged the life span and increased reproductive capacity through anti-oxidative stress pathway involving enhancing the activity of SOD1 and CAT and inhibiting lipofuscin accumulation | [ |
| Keratoconus corneal stroma cells | Keratoconus cells were treated with low dose of RF at 0.167 µg/mL | Increasing gene expression of antioxidant enzymes: aldehyde dehydrogenase 3A1, CAT, enolase 1, GPx 1, haem oxygenase 1, SOD 1 and transketolase | RF improved the synthesis of a normal extracellular matrix and downregulated ROS level in keratoconus. It was quatified by the total collagen protein in the keratoconic stroma. | [ |
| Diabetes-induced cardiac dysfunction | RF at 20 mg/kg was treated after streptozotocin-induced diabetes type I. | SOD↑, MDA↓, HO-1 protein level↑ | RFK can reduced the risk of cardiac dysfunction by increasing antioxidant, HO-1 and decreasing CTGF levels as well as improving lipid profile | [ |
| Diabetes mellitus type-2 | RF at 10 and 20 mg/kg was treated after alloxan-induced DM | SOD↑, catalase↑, GSH↑, MDA↓ | Decreased pancreatic activity, restored ant-oxidant enzyme activity, decreased FBG level while calcium level and GLUT-4 expression was increased | [ |
| Cardiac abnormalities in experimental atherosclerosis in rat | RF at 40 mg/kg together with CoRNS after hypolipidemic induction | SOD↑, CAT↑, GPx↑ | CoRNS significant reduced lipid profile: LDL and cardiac enzymes (LDH, ALT, AST, ALP) with enhanced levels of HDL and antioxidants. | [ |
| GTN-induced brain oxidative toxicity | RF at 100 mg/kg was treated before GTN-induced migraine | Lipid peroxidation↓, GSH↑, GPx↑ | RF with selenium administration protected against GTN-induced brain oxidative toxicity by protecting brain MMCA activity, inhibiting free radicals and supporting the antioxidant redox system. | [ |
| Migraine model | RF 100 mg/kg was treated before GTN-induced migraine | Lipid peroxidation↓, GSH↑ | RF and vitamin E had a protective effect on the GTN-induced brain injury by inhibiting free radical production, regulation of calcium-dependent processes, and supporting the antioxidant redox system. | [ |
Figure 3Flavin adenine dinucleotide (FAD) activates the glutathione reductase (GR) by transferring hydrogen for conversion of glutathione disulfide (GSSG) to glutathione (GSH).
Evidence of RF on the attenuation of reperfusion oxidative injury.
| Model | RF Dose | Key findings | Conclusions | References |
|---|---|---|---|---|
| Stroke-induced brain damage (neuroprotection against excitotoxicity) | RF at 0.05–0.5 mM before glutamate or NMDA treatment | RF at the concentrations of 0.2, 0.3, and 0.4 mM were significantly neuroprotective against glutamate and NMDA. | RF ameliorate glutamate or NMDA-mediated excitotoxicity to CGCs | [ |
| Cortical contusion injury (CCI) | RF treatment with 7.5 mg/kg, i.p; n = 7, 15 min after injury. A second dose was applied after 24h after injury. | Reducing brain edema formation, and inhibit GFAP+ expression, improve behavioral function. | Administration of RF following CCI of the frontal cortex improves recovery of function following injury | [ |
| Cortical contusion injury (CCI). | RF was treated after CCI:a combination of 1 mmol/kg MgCl2 and 7.5 mg/kg RF | The combination of MgCl2 and RF improved the functional recovery while the half-dose combination did not. | RF and magnesium infusions improved functional recovery to a greater extent than either alone following a frontal cortical contusion injury in rats | [ |
Antinociception and anti-inflammation effects of RF in animal model.
| Animal Model | RF Doses/Models | Major Outcome | References |
|---|---|---|---|
|
| |||
| Acetic acid-induced abdominal constructions, formaldehyde-induced nociceptive response and hot-plate models in mice | RF at 3–100 mg/kg i.p. injection 1 h before acetic acid-induced model, RF at 6 or12 mg/kg i.p. injection 1 h before formaldehyde-induced nociceptive response, and RF at 50 mg/kg i.p. injection 1 h before formaldehyde-induced hindpaw edema | A dose-dependent RF inhibited the nociceptive response produced by acetic acid. Pre-treatment RF remarkably reduced the acute nociceptive response induced by formaldehyde in the second phase, but not in the hot-plate model. RF moderately inhibited formaldehyde-induced hindpaw edema. | [ |
| Formalin-induced and carrageenan-induced paw edema, and spinal nerve ligation models in rat | RF at 1–50 mg/kg oral administration 30 min before formalin test and 6.25–150 mg/kg immediately after carrageenan injection | Second phase treatment with RF produced a significant dose-dependent inhibition in flinching behavior produced by formalin and RF at 25 mg/kg dose had peak antinociceptive effect in formalin-induced model. RF reduced hyperalgesic effect, highest effect at 75 mg/kg dose. In addition, a dose- and time-dependent RF treatment reduced by carrageenan-induced edema, but not tactile allodynia in the spinal nerve ligation models. Moreover, antinociceptive effect of RF can be reversed by glibenclamide and NG-L-nitro-aeginie methyl ester. | [ |
| Formalin-induced nociceptive response, carrageenan-induced paw edema, LPS-induced febrile response, and cotton pellet-induced formation of fibrovascular tissue models in rat | RF at 25, 50, 100 mg/kg i.p. injection 30 min before formalin-induced nociceptive response, carrageenan-induced paw edema, RF at 50 or 100 mg/kg immediately or 2 hr after LPS-induced the febrile response, and RF at 50 or 100 mg/kg i.p. 7 days after s.c. implantation of a cotton pellet-induced fibrovascular tissue | RF inhibited the nociceptive response in the mouse formalin test, markedly in second phase. RF was dose-dependently reduced the mechanical allodynia and the paw edema induced by carrageenan and inhibited the fever induced by LPS. Moreover, the formation of fibrovascular tissue induced by s.c. implant of a cotton pellet was inhibited. Therefore, RF prevents prolonged inflammatory response. | [ |
| Zymosan-induced peritonitis in Swiss mice | RF at 20, 50, 100 mg/kg i.p. injection 30 min before zymosan administration; RF at 50 mg/kg in combination with 5 mg/kg morphine | RF at 50 and 100 mg/kg induced antinociceptive-related body writhes and RF at 100 mg/kg dose suppressed intraperitoneal PMN influx. On the other hand, RF co-injected with morphine at low dose had antinociceptive effect and also reduced levels of proinflammatory cytikines such as TNF-α, IL-12p07, and IFN-γ according to RF dose and the time of injection. | [ |
|
| |||
| Toxin-induced shock (LPS-induced shock and | RF at 2.5, 5, 10, and 20 mg/kg bolus injection 6 h after LPS injection or SEB–D-galactosamine injection. RF at 2.5, 5, 10, 20 mg/kg 1 day before | RF decreased the mortality of endotoxin- and exotoxin-induced shock, gram-negative and gram-positive bacterial infection including long-term treatment. In addition, RF reduced levels of plasma inflammatory cytokines, including TNF-, IL-1β, IL-6, IFN-γ, MCP-1, MIP-2, and NO level. Moreover, co-administration RF with APC ameliorated survival rate of toxin-induced shock. | [ |
| LPS-induced shock model and bacterial infection model in mice | RF at 2.5, 5, 10, 20, 40, and 80 mg/kg/6h i.v. infusion after 6 h LPS injection. RF at 80 mg/kg/6 h after 1 h | RF protected mice against the mortality in both toxin shock and infection models, but RF reduced only the level of IL-6 and NO in plasma. In addition, RF decreased the elevation of TNF-α, IL-1β, MPC-1, IL-6, and NO level in plasma. | [ |
| LPS-induced shock model in mice | RF at 2.5 or 10 mg/kg for 6 h continuous i.v bolus administration with or without aminolevane® or single dose injection with or without amino acids or valine after 6 h LPS injection. | RF at 10 mg/kg administered continuously for 6 h reduced morbidities on LPS- induced shock model, and was better with aminolevane® combination treatment. RF treatment in combination with tryptophan, isoleucine, proline, threonine, alanine or valine had improved the survival rate, but only valine was significantly effective. Moreover, RF reduced IL-6, lactic acid level, but increased glucose level. | [ |
| Endotoxin-induced shock in mice | RF at 20 mg/kg i.v. administered after 6 h LPS injection | RF decreased the number of IL-6 and MIP-2 and NO levels in plasma. RF also reduced IL-6 and MIP-2 levels in lung, but inhibited only MIP-2 level in liver. However, RF reduced IL-6 mRNA expression in lung, but MIP-2 mRNA expression was inhibited in liver and kidney. Additionally, iNO expression was inhibited by RF. | [ |
| Olive oil-triggered paw swelling and collagen-induced arthritis models in mice | RF at 20 mg/kg i.p. administration before oil injection or after collagen-induced arthritis | RF inhibited the paw swelling induced by olive oil, affecting a reduction in neutrophil-dependent reaction. However, RF could not inhibit delayed type hypersensitivity reactivity and collagen II arthritis. | [ |
| LPS-induced shock model in mice | RF at 1 and 10 mg/kg i.p. injection at 2 and 0 h before LPS administration | RF significantly suppressed the LPS-induced lethality in mice septic shock model and RF have protective effect through up-regulated the expression of HSP25 in the lung and heart. | [ |
| Zymosan-induced peritonitis in different C57BL/6J, BALB/c and CBA mice strains | RF at 50 mg/kg i.p. co-injection with zymosan (40 mg/kg) | RF co-treatment with zymosan reduced pain symptoms. Anti-inflammatory effects of RF are strain-specific manner. Particularly, peritoneal leukocytes (PTL) accumulation was inhibited in BALB/c and CBA strains, but was prolonged in C57BL/6J strain. The expression of iNOS was delayed (C57BL/6J) or inhibited (BALB/c and CBA) in PTL lysates as well as the prolonged (C57BL/6) or inhibited (BALB/c) intraperitoneal accumulation of MMP-9. | [ |
| Zymosan-induced peritonitis in Swiss mice | RF at 0, 20, 50, or 100 mg/kg by co-injection, pre-injection or post-injection in zymosan-induced peritonitis | RF itself induced nociceptive-related body writhes, but effectively reduces zymosan-induced writhing response on influence of pre-injection or post- injection. RF also reduced the evaluation number of PLTs, mainly PMN and an increase in inflammation-related cytokines and MMP-9 with dose- and administration time-dependent effect. | [ |
| LPS-induced acute lungs injury in rat | RF at 30 mg/kg, p.o. for 7 days before LPS intranasally (i.n.) | RF reduced interstitial edema, hemorrhage, infiltration of inflammatory PMNs, and destruction of lung parenchyma as well as decreased the iNOS level, but enhanced GSH, GR, GRx, and CAT expression. | [ |
| Zymosan-induced inflammation in mice and in vitro macrophages | RF at 50 mg/kg i.p. injection 30 min either before zymosan, together with zymosan, or 2, 4, 6 h after i.p. zymosan injection. | RF causes both the inhibition of expression and release of HMGB1 in time-dependent manner. | [ |
Figure 4RF is converted by RFK into FMN and FAD, which is essential cofactor the phagocytic NADPH oxidase 2 (Nox2) to generate ROS. Therefore, RF deficiency is incapable of ROS production by the phagocyte Nox2, which is crucial to inactivate phagocytosed microbes and to regulate the inflammatory response in innate immune cells. TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor 1.
Figure 5Activation of NADPH oxidase and microbicidal systems during phagocytosis. Complement and antibody receptors (CRs and FcRs) promote the uptake of micro-organisms by neutrophils, which, in turn, trigger the degranulation and production of ROS.
Figure 6Role of RF as an adjuvant in cisplatin based chemo radiotherapy [75]. RF stimulates apoptotic factors and downregulates anti-apoptotic factors. Additionally, it activates p53, which also results in an amplification of apoptosis. The inhibitory effects of RF in respect to the deteriorate effect of cisplatin are also shown. On the one hand, it inhibits the downregulation of antioxidant enzymes and proteins; on the other, RF downregulates pro-inflammatory cytokines.
Figure 7Implications of RF deficiency on health [75].
Figure 8Conversion oxidized glutathione (GSSG) to the reduced form (GSH) by glutathione reductase requires RF in the FAD co-enzyme form for its activity. G-6P-D, glucose-6-phosphate dehydrogenase [98].
Figure 9RF in functional food and encapsulation products.
Techniques and characteristic of micro/nanoencapsulation of encapsulated RF.
| Encapsulation Techniques | Wall | Illustration of Characteristics | Purpose | Size | References |
|---|---|---|---|---|---|
| Cold-set gelation | Whey protein |
| Proofing suitability of encapsulation system for intestinal delivery using in vitro and in vivo models | 1.8 mm | [ |
| Cross-linking of HIU-treated SPI with TGase | Soy protein isolated (SPI) |
| Demonstrating of HIU-treated SPI–TGase cold gel for longer retention in the gastrointestinal system | 3 mm | [ |
| Ionotropic gelation | Alginate/chitosan nanoparticles |
| Establishing of alginate/chitosan nanoparticle for controlled release in different temperature and pH conditions | 119.5 ± 49.9 nm | [ |
| Ultrasonication | Soy protein/dextran |
| Providing basic design of soy protein/dextran nanogel for effective and suitable carriers for bioactive compounds | 143.3 nm | [ |
| Bioconjugation | Phenylalanine ethyl ester–alginate conjugated (PEA) |
| Illustrating a sonication method of self-assembled nanoparticles formed by PEA conjugate without cytotoxicity against cell lines | 200 nm | [ |
| Supercritical fluid technology | Fully hydrogenated canola oil |
| Evaluating surfactant and molecular weight of stabilizer from supercritical fluid technology for development of solid lipid nanoparticles | 104 ± 5.7 nm | [ |
| Coprecipitation-Crosslinking-Dissolution technique (CCD-technique) | Human serum albumin |
| Demonstrating a simple coprecipitation method of albumin submicron particles with good biocompatibility | 900 ± 1000 nm | [ |